Hormones increase side effects, complicate treatment decision for prostate cancer patients

October 21, 2003

SALT LAKE CITY, UTAH---A common treatment for some men with prostate cancer at risk of recurring may lead to prolonged survival, but a new study shows at what cost. In an oral presentation today at the 45th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Salt Lake City, Utah, Steven J. Feigenberg, M.D., a radiation oncologist at Fox Chase Cancer Center, explained the increased risk of both urinary and gastrointestinal side effects experienced by men receiving hormonal therapy with radiation therapy. "Over the last few years, adjuvant hormonal therapy has demonstrated disease-free and overall survival benefits for patients with high risk prostate cancer," Feigenberg said. "Our study shows that the addition of hormones increased the risk of both gastrointestinal and genitourinary side effects. In addition, the side effects worsened the longer the hormones were administered."

For the study, researchers evaluated 1,204 men who were treated with radiation therapy (3-D conformal radiation therapy) between May 1989 and November 1998. Of these men, 942 did not receive hormones while 155 and 106 patients received short- and long-term hormone suppression (androgen deprivation), respectively.

"The only independent predictor of urinary side effects, including frequent urination, was the use of hormone therapy while the use of hormones was one of four independent predictors of GI-related side effects," explained Feigenberg. "Moderate to severe gastrointestinal side effects were recorded for 17 percent of patients not taking hormone therapy, while 18 percent of patients receiving short-term hormones and 26 percent of patients receiving long-term hormones reported GI problems five years after treatment."

The findings for genitorurinary side effects showed that 8 percent of patients not taking hormones reported serious side effects while 8 and 14 percent of patients taking short- and long-term hormones, respectively, had moderate to severe side effects.

"The use of short and long-term androgen deprivation appears to significantly increase the risk of moderate to severe GU and GI side effects, but we know that hormone therapy can extend the lives of men with advanced disease," Feigenberg concluded. "These results make the balance of survival versus quality of life more difficult for patient decision making."

Other authors of the study include Alexandra L. Hanlon, Ph.D., Eric M. Horwitz, M.D., and Alan Pollack, M.D., Ph.D., of Fox Chase Cancer Center.
-end-
Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic, clinical, population and translational research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu or call 1-888-FOX CHASE.

Fox Chase Cancer Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.